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and no change to modest improvement from admission
to follow-up (0–1 points). CONCLUSIONS: Antidepres-
sant agents in this analysis were associated with modest
improvement in maladaptive behavior as assessed by the
PDGRS. New treatment modalities that improve mal-
adaptive behavior along with depressive symptomatology
in older patients would be beneficial. Further controlled
studies are needed to better understand these findings.
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OBJECTIVES: An array of antidepressant agents are
available in the treatment of geropsychiatric patients with
depression. While most current agents, such as the selec-
tive serotonin reuptake inhibitors (SSRI’s) (e.g., fluoxe-
tine; sertraline) and agents acting upon both serotonin
and norepinephrine (e.g., mirtazapine; venlaxafine), are
reasonably effective in ameliorating depressive symptom-
atology, less is known about the impact of these agents
on other common areas of deficit in older depressed pa-
tients, such as cognition. This study examines change in
cognitive functioning in geropsychiatric patients (age 55
and older) with major depression (ICD-9-CM codes
296.20-296.36) treated with fluoxetine (n  269), mir-
tazapine (n  275), sertraline (n  713), or venlaxafine
(n  259). METHODS: Data were obtained from the
CQISM Outcomes Measurement System, a Joint Com-
mission of Accredited Hospital Organizations (JCAHO)
ORYX accepted performance improvement system,
which tracked patients admitted to geropsychiatric inpa-
tient programs in 111 general hospitals across 33 states
between 1997–1999. Cognitive functioning was mea-
sured at admission and discharge using the Mini-Mental
State Examination (MMSE) (Folstein, Folstein, & McHugh,
1975). A Medication Usage Questionnaire was used to
track medications prescribed to patients just prior to ad-
mission and at discharge. One-way Analyses of Variance
and if significant, Tukey’s pairwise comparisons, were
used to compare medication groups. RESULTS: At ad-
mission, patients exhibited moderate evidence of cogni-
tive impairment (Mean MMSE score of 21 out of 30).
Medication groups were indistinguishable on change
scores in cognitive functioning from time of admission to
discharge (average length of stay around 16 days). The
average change score on the MMSE was 1.1 to 1.6 points,
suggesting very mild improvement. CONCLUSIONS: Anti-
depressant agents in this analysis were associated with
modest improvement in cognitive functioning as assessed
by the MMSE. New treatment modalities that improve
cognition along with depressive symptomatology in older
patients would be beneficial.
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OBJECTIVES: To compare the change in health care uti-
lization and costs from one year before (preperiod) and
one year after (postperiod) starting treatment with ris-
peridone or olanzapine in schizophrenia patients in a
Veterans Administration population. METHODS: Pa-
tients with a diagnosis of schizophrenia (ICD-9 CM code
295) in the preperiod, who had an initial prescription for
risperidone or olanzapine dispensed between 3/97 and
3/99, were included. Patients who received any atypical
antipsychotic in the preperiod were excluded. Compari-
sons of average change in utilization and cost from the
preperiod to the postperiod were made between the
groups for: inpatient hospitalizations, outpatient clinic
visits, medications, and total health care cost. Analysis of
covariance was used to analyze the data using age, gen-
der, and race as covariates. RESULTS: 304 patients in
the olanzapine group and 344 in the risperidone group
were included. The olanzapine group had significantly
more inpatient admissions per patient (0.09 vs. 0.24,
p  0.026), longer inpatient lengths of stay (4.3 days
vs. 4.2 days, p  0.004), and higher cost of inpatient
admissions ($2735 vs. $3226, p  0.003) than the ris-
peridone group. There was a significantly lower cost of
antipsychotic for the risperidone group than for the olan-
zapine group ($650 vs. $1660, p  0.001). The mean
daily doses were 3.4 mg of risperidone and 12.0 mg of
olanzapine. The olanzapine group also had a significantly
higher change in cost for all drugs ($1492 vs. $683, p 
0.001) and all health care costs ($5,665 vs. $1,167, p 
0.001) than the risperidone group. CONCLUSIONS:
The changes in total health care costs, number, length of
stay, and cost of inpatient admissions, and medication
costs for risperidone-treated patients were significantly
lower compared with olanzapine-treated patients.
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OBJECTIVES: Attention-deficit/hyperactivity disorder
(ADHD) is the most commonly diagnosed psychiatric
disorder among children in the US. However, the social
